Record-Breaking Price Movement
On 22 July 2026, Parmax Pharma Ltd’s share price opened and traded steadily at Rs.107.06, setting a new 52-week and all-time high. The stock outperformed its sector by 3.75% on the day, registering a daily gain of 1.99%, while the broader Sensex declined by 0.82%. This price surge is the culmination of a strong upward trajectory, with the stock gaining for 21 consecutive trading sessions and delivering a total return of 51.3% during this period.
Comparative Performance Against Benchmarks
Parmax Pharma’s performance over various time frames has been notably robust compared to the Sensex benchmark. Over the past week, the stock rose by 10.37%, while the Sensex marginally declined by 0.45%. The one-month return stands at an impressive 51.3%, contrasting with the Sensex’s slight fall of 0.34%. Over three months, the stock surged by 225.91%, whereas the Sensex dropped by 2.14%. The year-to-date return is even more striking at 216.46%, against the Sensex’s negative 9.84%. Over a longer horizon, the three-year gain of 260.47% far exceeds the Sensex’s 15.22% rise, and the five-year return of 88.15% also outpaces the Sensex’s 45.42% growth.
Technical Indicators Confirm Bullish Momentum
The technical landscape for Parmax Pharma Ltd is strongly positive. The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained upward momentum. The overall technical trend is classified as bullish, a status that was upgraded from mildly bullish on 8 June 2026 when the stock was priced at Rs.48.81.
Key technical indicators such as MACD, Bollinger Bands, KST, and Dow Theory all reflect bullish signals on both weekly and monthly timeframes. Although the Relative Strength Index (RSI) shows bearish readings, the broader technical consensus supports the ongoing uptrend. Immediate support is identified at the 52-week low of Rs.22.60, while the stock has decisively surpassed previous resistance levels at Rs.39.81 (200 DMA), Rs.46.43 (100 DMA), and Rs.87.62 (20 DMA).
Volume and Delivery Trends
Trading volumes have also shown a positive trend, with a 31.22% increase in delivery volumes over the past month and a significant 71.62% rise in delivery volume on the day of the new high compared to the five-day average. This suggests strong participation in the stock’s recent rally, supporting the price appreciation.
Valuation and Financial Metrics
Despite the impressive price performance, Parmax Pharma Ltd remains a loss-making entity, with no reported price-to-earnings ratio due to negative earnings. The company’s price-to-book value stands at -6.39x, and EV/EBITDA and EV/EBIT ratios are negative at -14.01x and -10.90x respectively, reflecting ongoing losses at the operating level. The EV/Sales multiple is 4.14x, while EV/Capital Employed is 10.62x. Dividend metrics are not applicable as the company has not declared dividends.
Quality and Financial Health Assessment
Parmax Pharma Ltd’s overall quality grade is below average, based on long-term financial performance. The company exhibits below-average management risk, growth, and capital structure metrics. Over the past five years, sales have declined by 14.3%, and EBIT has contracted sharply by 225.63%. The average EBIT to interest coverage ratio is weak at 0.66x, although the company benefits from a net cash position with negative net debt and zero promoter share pledging.
Return on capital employed (ROCE) and return on equity (ROE) remain weak at -28.89% and 5.12% respectively. The tax ratio is 100%, and the dividend payout ratio is zero, consistent with the company’s loss-making status. Institutional holdings are minimal, indicating limited institutional participation.
Short-Term Financial Trends
Recent quarterly data shows a mixed picture. The company reported its highest quarterly earnings per share (EPS) at a loss of Rs.-1.55, while profit after tax (PAT) for the latest nine months declined by 50.12% to Rs.-3.39 crores. Net sales over the last six months fell by 31.23% to Rs.7.64 crores. Debtors turnover ratio is at a low 3.83 times, and profit before tax excluding other income for the quarter was Rs.-2.30 crores, the lowest recorded.
Summary of the Stock’s Journey
Parmax Pharma Ltd’s stock has demonstrated a remarkable recovery and growth phase, culminating in the all-time high price of Rs.107.06 on 22 July 2026. The stock’s consistent gains over 21 trading sessions and strong outperformance relative to the Sensex and its sector highlight a significant shift in market sentiment. Technical indicators and volume trends corroborate the bullish momentum, while valuation and quality metrics reflect the company’s ongoing financial challenges.
This milestone represents a key moment in the company’s market journey, underscoring the dynamic nature of its stock performance within the Pharmaceuticals & Biotechnology sector.
